Free Trial

BioLineRx (BLRX) SEC Filings & 10K Form

BioLineRx logo
$2.44 -0.09 (-3.37%)
As of 11:46 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Recent BioLineRx SEC Filings

DateFilerForm TypeView
03/31/2025
6:01 AM
BioLineRx (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
03/31/2025
6:04 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/21/2025
6:11 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/17/2025
6:09 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/10/2025
5:51 PM
BioLineRx (Subject)
INTRACOASTAL CAPITAL, LLC (Filed by)
Form SCHEDULE 13G
01/07/2025
9:12 AM
BioLineRx (Filer)
Form 424B5
01/07/2025
9:15 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/06/2025
7:55 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/27/2024
3:16 PM
BioLineRx (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
11/25/2024
6:07 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/21/2024
5:50 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/21/2024
5:44 AM
BioLineRx (Filer)
Form 424B5
11/05/2024
8:06 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/16/2024
6:08 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/19/2024
3:30 PM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/15/2024
6:06 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/30/2024
6:16 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/28/2024
6:11 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/24/2024
6:05 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/06/2024
6:14 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/17/2024
6:12 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/10/2024
6:24 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)

Remove Ads

Related Companies and Tools


This page (NASDAQ:BLRX) was last updated on 4/8/2025 by MarketBeat.com Staff
From Our Partners